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Objectives
To review the literature to determine the sensitivity and
speciﬁcity of gallium-68 prostate-speciﬁc membrane
antigen (68Ga-PSMA) positron-emission tomography
(PET) for detecting pelvic lymph node metastases in
patients with primary prostate cancer (PCa), and the
positive predictive value in patients with biochemical
recurrence (BCR) after initial curative treatment, and, in
addition, to determine the detection rate and management
impact of 68Ga-PSMA PET in patients with BCR after
radical prostatectomy (RP).
Materials and Methods
We performed a comprehensive literature search. Search
terms used in MEDLINE, EMBASE and Science Direct were
‘(PSMA, 68Ga-PSMA, 68Gallium-PSMA, Ga-68-PSMA or
prostate-speciﬁc membrane antigen)’ and ‘(histology, lymph
node, staging, sensitivity, speciﬁcity, positive predictive value,
recurrence, recurrent or detection)’. Relevant abstracts were
reviewed and full-text articles obtained where possible.
References to and from obtained articles were searched to
identify further relevant articles.
Results
Nine retrospective and two prospective studies described the
sensitivity and speciﬁcity of 68Ga-PSMA PET for detecting
pelvic lymph node metastases before initial treatment, which
ranged from 33.3% to 100% and 80% to 100%, respectively.
In eight retrospective studies, the positive predictive value of
68Ga-PSMA PET in patients with BCR before salvage lymph
node dissection ranged from 70% to 100%. The detection rate
of 68Ga-PSMA PET in patients with BCR after RP in the PSA
subgroups <0.2 ng/mL, 0.2–0.49 ng/mL and 0.5 to <1.0 ng/
mL ranged from 11.3% to 50.0%, 20.0% to 72.7% and 25.0%
to 87.5%, respectively.
Conclusion
The review results showed that 68Ga-PSMA PET had a high
speciﬁcity for the detection of pelvic lymph node metastases in
primary PCa. Furthermore, 68Ga-PSMA PET had a very high
positive predictive value in detecting lymph node metastases in
patients with BCR. By contrast, sensitivity was only moderate;
therefore, based on the currently available literature, 68Ga-
PSMA PET cannot yet replace pelvic lymph node dissection to
exclude lymph node metastases. In the salvage phase, 68Ga-
PSMA PET had both a high detection rate and impact on
radiotherapy planning in early BCR after RP.
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Introduction
Prostate cancer (PCa) has the second-highest incidence of all
cancers in men worldwide [1]. Disease staging at primary
diagnosis and at early biochemical recurrence (BCR) after
initial curative treatment is important in determining optimal
treatment strategy, and prognosis. Traditionally, CT or MRI
is used for nodal staging, and bone scintigraphy (using
99mTc-labelled bisphosphonates) is used to detect bone
metastases; however, all techniques have limited sensitivity for
detecting lymph node and/or bone metastases [2]. In current
practice, therefore, an extended pelvic lymph node dissection
(PLND) is performed to accurately stage patients with a risk
of > 5% of having nodal metastases [3].
The use of gallium-68 (68Ga)-prostate-speciﬁc membrane
antigen (PSMA) for positron-emission tomography (PET) in
patients with PCa was ﬁrst described in 2012 [4]. PSMA is a
type 2 transmembrane glycoprotein that is highly
overexpressed in PCa tumours and PCa metastasis. PSMA
represents a large extracellular domain which can be targeted
by ligands for imaging and treatment purposes [5].
Expression of PSMA is increased in more aggressive PCa [6].
Since the ﬁrst report of the use of 68Ga-PSMA PET in 2012,
there has been a growing body of evidence that this technique
is superior to other imaging approaches, both in the primary
as well as in the recurrence setting [7,8]. 68Ga-PSMA PET has
demonstrated a signiﬁcantly higher detection rate than
choline PET/CT and a high overall impact on management
[9]. The 2019 European Association of Urology guideline
recommends performing a PSMA PET at early BCR (>0.2 ng/
mL) after initial treatment if the result will inﬂuence
subsequent treatment decisions (level of evidence 2b; weak
recommendation) [3].
The primary aim of the prsent review was to obtain insight
into the sensitivity and speciﬁcity of 68Ga-PSMA PET for the
detection of pelvic lymph node metastases in patients with
primary PCa. In addition, we aimed to evaluate the positive
predictive value of 68Ga-PMSA PET for the detection of
lymph node metastases in patients with BCR after initial
curative treatment. The secondary aim was to assess the
detection rate of 68Ga-PSMA PET in patients with BCR after
radical prostatectomy (RP), the location of PCa recurrence
and the impact of 68Ga-PSMA PET outcome on the planning
of salvage treatment in these patients.
Methods
In May 2019, we performed a comprehensive literature
search. Relevant manuscripts were found through searches of
Medline, EMBASE and Science Direct databases. To review
the sensitivity, speciﬁcity and positive predictive value of
68Ga-PSMA PET, the following search terms were used:
‘(PSMA, 68Ga-PSMA, 68Gallium-PSMA, Ga-68-PSMA or
prostate-speciﬁc membrane antigen)’ in combination with
‘(histology, lymph node, staging, sensitivity, speciﬁcity or
positive predictive value)’. To review the detection rate of
68Ga-PSMA PET in patients with BCR after RP the following
search terms were used: ‘(PSMA, 68Ga-PSMA, 68Gallium-
PSMA, Ga-68-PSMA or prostate-speciﬁc membrane antigen)’
in combination with ‘(recurrence, recurrent or detection)’.
Studies were initially selected based on title, followed by
screening on abstract. References to and from obtained
articles were searched to identify further relevant articles.
Only articles in the English language were included.
For the ﬁrst section of the present review, we included all
studies that determined the diagnostic ability of 68Ga-PSMA
PET for preoperative lymph node staging of PCa, using
histopathology as the ‘gold standard’. The sensitivity,
speciﬁcity and positive predictive value were retrieved from
the studies included in our review. The studies were divided
into two categories: (1) patients undergoing a 68Ga-PSMA
PET before initial treatment consisting of RP with extended
PLND, i.e. the primary diagnosis and (2) patients with BCR
after initial treatment undergoing 68Ga-PSMA PET, followed
by salvage PLND, i.e. salvage therapy. We excluded studies
that included a mixed group of patients (primary diagnosis
and salvage therapy) and did not present the results
separately. Studies reporting only the per-region sensitivity
and speciﬁcity were also excluded.
For the second section of this review, we included studies that
reported the detection rate of the 68Ga-PSMA PET in patients
with BCR after RP and a PSA value < 1.0 ng/mL. The
detection rates were subdivided into three PSA categories:
0.01–0.19 ng/mL; 0.20–0.49 ng/mL; and 0.50 to <1.00 ng/mL.
Finally, the sites of PCa recurrence were collated when
reported in patients with BCR after RP without additional
treatment after RP. Therefore, studies describing patients who
received radiotherapy and/or androgen deprivation therapy
(ADT) before 68Ga-PSMA PET were excluded.
The results of the included studies are reported in the text as
ranges; a meta-analysis was not performed. The individual
reported results are provided in Tables 1–4.
Results
Diagnostic Performance of 68Ga-PSMA PET for Pelvic
Lymph Node Metastases
Eleven studies were included in this review that presented
data on the sensitivity and speciﬁcity of 68Ga-PSMA PET for
detection of pelvic lymph node metastases in men with newly
diagnosed PCa (Table 1, Fig. 1) [8,10–19]. Two prospective
studies, including a total of 63 patients, showed a per-patient
sensitivity (range) and speciﬁcity (range) of 64–100% and 90–
95%, respectively. The per-node sensitivity and speciﬁcity
were 50–58% and 96–100%, respectively [15,18]. Nine
retrospective studies, including 696 patients, showed a per-
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patient sensitivity and speciﬁcity of 33.3–100% and 80–100%.
The per-node sensitivity and speciﬁcity was 24.4–96.1% and
98.6–100%, respectively [8,10–14,16,17,20].
In this review, eight retrospective studies were included,
reporting the positive predictive value of 68Ga-PSMA PET in
detecting pelvic lymph node metastases in patients with BCR
A B
Fig. 1 Axial and sagittal plane gallium-68 prostate-speciﬁc membrane antigen positron-emission tomography /CT images of two patients with
locoregional lymph node recurrence after initial curative treatment. The metastasis in patient A is located in the obturator area and the metastasis in
patient B is located in the presacral area.
Table 1 The per-patient and per-node sensitivity and speciﬁcity of gallium-68 prostate-speciﬁc membrane antigen positron-emission tomography/CT in
patients undergoing radical prostatectomy with extended lymph node dissection (primary diagnosis).
Author (year) Total number
of patients
(patients
with LNM)
Number of lymph
nodes dissected
Mean  SDMedian
(IQR)
Per-patients
sensitivity, %
Per-patients
speciﬁcity, %
Per-node
sensitivity
Per-node
speciﬁcity
Budaus (2016) [10] 30 (12) 20.3
18.5 (13.5–27.5)
33.3 100 – –
Gupta (2017) [8] 12 (7) 20.25
20
100 80 66.67% 98.61%
Maurer (2016) [11] 130 (41) –
21 (12–30)
65.9 98.9
Obek (2017) [12] 51 (15) 20.2  8.5
18.5
53.3 86.1 – –
Thalgott (2018) [13] 73 (25) 26.1  16.9
23 (17–29)
60 100
Van Leeuwen (2018) [14] 140 (51) –
16 (12–21)
53 88 – –
Van Leeuwen (2017) [15] 30 (11) 17.8  7
16 (12–20)
64 95 58% 100%
Yaxley (2019) [16] 208 (55) –
13
38.2 93.5 24.4% 99.5%
Zhang (2017) [17] 42 (15) 7.095
–
93.3 96.3 96.08% 99.65%
Park (2018)* [18] 33 (3) 11.6
–
100 90 50% 98.38%
Yilmaz ([19]) 10 (2) –
–
100 100 – –
IQR, interquartile range; LNM, lymph node metastases. *Gallium-68 prostate-speciﬁc membrane antigen positron-emission tomography (68Ga-PSMA PET)/MRI was used instead of
68Ga-PSMA PET/CT.
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after initial curative treatment [21–28]. All patients
underwent salvage PLND, and histopathology was used as the
gold standard reference. The positive predictive value, among
the total of 290 patients included, ranged from 70% to 100%
(Table 2) [21–28].
Detection Rate of 68Ga-PSMA PET in Patients with
Biochemical Recurrence after Radical
Prostatectomy
The detection rates of 68Ga-PSMA PET in men with BCR
after RP are shown per PSA subgroup in Table 3. Eight
studies reported the detection rate of 68Ga-PSMA PET in
patients with a PSA value <0.2 ng/mL [29–36]. This included
286 patients. Eighty-six of the 286 patients (30.1%) had a
positive 68Ga-PSMA PET, with the detection rate ranging
from 11.3% to 50.0% [29–36].
Eighteen studies reported the detection rate of 68Ga-PSMA PET
in patients with a PSA 0.20–0.49 ng/mL [21,29–45]. Combined,
this involved 1078 patients. Of the 1078 patients, 507 (47.0%)
had a positive 68Ga-PSMA PET. At this PSA range, the
detection rate varied from 20.0% to 72.7% [21,29–45].
Fifteen studies described the detection rate of 68Ga-PSMA
PET in patients with a PSA level of 0.50 to <1.0 ng/mL
[21,29–33,35–38,41–45]. Collectively, these studies included
567 patients. Of these 567 patients, 367 (64.7%) had a
positive 68Ga-PSMA PET. The detection rate ranged from
25% to 87.5% [21,29–33,35–38,41–45].
Location of Prostate Cancer Recurrence Based on
the 68Ga-PSMA PET
In total, three studies reported the anatomical sites of 68Ga-
PSMA-positive lesions in patients with BCR after RP in the
absence of treatment between RP and 68Ga-PSMA PET.
The location of PCa recurrence in the different PSA groups
is shown in Table 4. Emmett et al. [36] and van Leeuwen
et al. [30], combined, identiﬁed 254 patients with a PSA
<1 ng/mL detecting a local recurrence only in 63 patients,
pelvic lymph node metastases  local recurrence in 55
patients, and distant metastases  local recurrence in 39
patients. Boreta et al. [34] included 125 patients with a PSA
<2.0 ng/mL. 68Ga-PSMA PET detected a local recurrence
only in eight patients, pelvic lymph node metastases  local
recurrence in 33 patients, and distant metastases  local
recurrence in 25 patients.
Discussion
Recently, the ability of imaging to detect PCa metastases and
PCa recurrence at very low PSA values has notably improved
after the introduction of the PSMA PET. We conducted this
review to determine the sensitivity, speciﬁcity and positive
predictive value of 68Ga-PSMA PET in detecting pelvic lymph
node metastases. Furthermore, we assessed the detection rates
of 68Ga-PSMA PET and the location of PCa recurrence in
patients with early BCR after RP. On the basis of the current
Table 2 The positive predictive value of gallium-68 prostate-speciﬁc membrane antigen positron-emission tomography/CT in patients undergoing
salvage lymph node dissection (salvage phase).
Author (year) Total number
of patients
Initial treatment (n) Number of
lymph nodes
dissected
Mean  SD
Median (IQR)
PPV per
patient, %
PPV per
region, %
Fendler (2019)* [21] 87 RP and/or RT – 84 84
Linxweiler (2018) [22] 25 RP (25) –
9 (5–14)
92 –
Mandel (2018)* [23] 23 RP (23) –
15
70 87.5
Pﬁster (2016) [24] 28 RP (23)
RT (3)
HIFU (2)
11
–
82 75.7 (per node)
Rauscher (2016) [25] 48 RP (45)
RT (3) –
–
93 94.6
Siriwardana (2017) [26] 35 RP (28)
Brachytherapy (5)
ERBT (1)
ERBT + brachytherapy (1)
–
9 (3–14)
91 –
Jilg (2017) [27] 30 RP (29)
RT (1)
–
33 (25.5–41.5)
100% 98.3
Herlemann (2016) [28] 14 RP (14) – – 86
EBRT, external beam radiation therapy; HIFU, high-intensity focused ultrasonography; IQR, interquartile range; PPV, positive predictive value; RP, radical prostatectomy; RT,
radiation therapy. *Patients underwent either gallium-68 prostate-speciﬁc membrane antigen positron-emission tomography (PET)/CT or PET/MRI.
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literature, we conclude that 68Ga-PSMA PET has an excellent
speciﬁcity and positive predictive value for the detection of
pelvic lymph node metastases in primary and recurrent PCa,
that the detection rate achieved by 68Ga-PSMA PET in
patients with BCR after RP increases in parallel with rises in
PSA values, and that the impact of PSMA in these men with
recurrent PCa is considerable.
The results of this review highlight the high speciﬁcity and
positive predictive value of 68Ga-PSMA PET in detecting
pelvic lymph node metastases. Most studies report a per-
patient speciﬁcity of 90% or higher [10,11,13,15–17,19]. This
high speciﬁcity is a result of the high expression of PSMA in
PCa and lymph node metastases, resulting in a high tumour
to background ratio [46–49].
An extended PLND is the gold standard for lymph node
staging in PCa, but lymph node metastasis can be missed
during extended PLND or misclassiﬁed during histological
examination. Increased sensitivity of extended PLND can
further increase the speciﬁcity of 68Ga-PSMA PET. This is
demonstrated by Horn et al. [50], who detected metastatic
tissue in 120 of 121 patients with a positive 68Ga-PSMA PET
using PSMA-targeted radioguided surgery. Owing to the high
speciﬁcity and positive predictive value of 68Ga-PSMA PET in
detecting pelvic lymph node metastases, it is not always
necessary to obtain histology to conﬁrm lymph node
metastasis in case of a positive 68Ga-PSMA PET result.
The speciﬁcity of 68Ga-PSMA PET for detecting local
recurrence or bone metastases is unknown because
Table 4 Detection rate and location of recurrence in patients without treatment between radical prostatectomy and gallium-68 prostate-speciﬁc
membrane antigen positron-emission tomography/CT at different PSA values.
Emmett (2017) [36] Van Leeuwen (2016) [30] Boreta (2019) [34]
PSA range 0.01–0.19 0.01–0.19 0.01–0.19
Total patients (total positive, percentage positive) 77 (45, 58.4%) 35 (11, 31.4%) 9 (3, 33.3%)
Recurrence fossa only 12 5 0
Pelvic lymph nodes  fossa 16 4 2
Distant metastases  fossa 17 2 1
PSA range 0.2–0.49 0.2–0.49 0.20–0.59
Total patients (total positive; % positive) 82 (56; 68.3) 28 (18; 64.3) 80 (39; 48.8)
Recurrence fossa only 22 10 6
Pelvic lymph nodes  fossa 23 5 22
Distant metastases  fossa 12 3 11
PSA range 0.50 to <1.0 0.5 to <1.0 0.60–1.19
Total patients (total positive; % positive) 25 (19; 76.0) 7 (4; 57.1) 24 (13; 54.2)
Recurrence fossa only 9 5 2
Pelvic lymph nodes  fossa 6 1 4
Distant metastases  fossa 4 1 7
Table 3 Detection rate of gallium-68 prostate-speciﬁc membrane antigen (PSMA) positron-emission tomography in different PSMA subgroups.
Author (year) Number of patients
(percentage positive scans)
Number of patients
(percentage positive scans)
Number of patients
(percentage positive scans)
PSA 0.50 to <1.00 ng/mL PSA 0.01–0.19 ng/mL (%) PSA 0.20–0.49 ng/mL
Kranzb€uhler (2018) [29] 9 (44.4) 11 (72.7) 8 (87.5)
Van Leeuwen (2016) [30] 35 (40.0) 28 (71.4) 7 (57.1)
Meredith (2016) [31] 124 (11.3) 79 (26.6) 45 (53.3)
Gupta (2017) [32] 11 (45.5) 16 (43.8) 17 (29.4)
Schmuck (2017) [33] 18 (38.9) 34 (55.9) 28 (60.7)
Emmett (2017) [36] 64 (50.0) 81 (67.9) 24 (79.2)
Boreta (2019) [34] 9 (33.3) 75 (52.0) –
Yilmaz (2019) [35] 16 (43.8) 17 (52.9) 14 (64.3)
Habl (2017)* [45] 42 (50.0) 21 (85.7)
Fendler (2019) [21] – 136 (38.2) 79 (57.0)
Berliner (2017) [37] – 33 (51.5) 11 (54.5)
McCarthy (2019) [38] – 63 (50.8) 21 (76.2)
Bashir (2019)* [39] – 28 (60.7) –
Farolﬁ (2019) [40] – 119 (34.5) –
Calais (2018) [41] – 153 (40.5) 117 (59.8)
Sanli (2017) [42] – 10 (20) 4 (25.0)
Eiber (2015) [43] – 19 (57.9) 33 (72.7)
Rauscher (2018) [44] – 134 (55.2) 138 (73.9)
Total 286 (30.1) 1078 (47.0) 546 (63.9)
*PSA level between 0.01 and 0.5 ng/mL.
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histopathological conﬁrmation is often not obtained; however,
the speciﬁcity of 68Ga-PSMA PET in detecting a local
recurrence is thought to be high because of the high efﬁcacy
of salvage radiotherapy with regard to local recurrence
detected by 68Ga-PSMA PET [36]. By increased PSMA
expression, fractures and Paget’s disease can mimic bone
metastases on 68Ga-PSMA PET, with high expression in the
vasculature of neo-angiogenesis. The speciﬁcity of 68Ga-
PSMA PET for early bone metastases is almost certainly
lower because of these benign conditions that also express
low levels of PSMA [51–54].
The speciﬁcity and sensitivity of 68Ga-PSMA PET for
detecting intraprostatic lesions at diagnosis is calculated on
the basis of whole prostate gland histology. The reported
speciﬁcity and sensitivity range from 92% to 100% and 60.1%
to 67%, respectively [55,56]. A high lesion to normal prostate
tissue ratio is seen in lesions with Gleason score ≥7 [55]. The
use of 68Ga-PSMA PET in the diagnostic pathway of PCa is
yet to be determined.
The sensitivity of 68Ga-PSMA PET for detecting lymph node
metastases, in contrast to the speciﬁcity, is only moderate.
The reported per-patient sensitivity ranges from 33.3% to
100%. The fact that the 68Ga-PSMA PET misses lymph node
metastases is highlighted by a lower per-node sensitivity,
which is in the range of 24.4–66.67%. Lymph node metastases
can be missed because of the lack of PSMA expression in 0–
9% of primary prostate tumours and lymph node metastases
[57,58]. Moreover, 68Ga-PSMA PET misses small lymph node
metastases [10,12,15,25,27]. In the studies by van Leeuwen
et al. [15], Budaus et al. [10] and Obek et al. [12] the 68Ga-
PSMA PET missed all lymph node metastases smaller than 2,
4 and 5 mm, respectively therefore, 68Ga-PSMA PET cannot
yet replace extended PLND to exclude pelvic lymph node
metastases.
As extended PLND is used as the gold standard reference, the
number of nodes removed inﬂuences the sensitivity of 68Ga-
PSMA PET. 68Ga-PSMA PET results can wrongly be
classiﬁed as true-negative if lymph node metastasis is missed
during extended PLND. Although there is no consensus
regarding the minimum number of lymph nodes that should
be removed during extended PLND, studies in which a low
number of lymph nodes are removed should be interpreted
with caution.
In the salvage phase, the detection rate of 68Ga-PSMA PET is
strongly correlated to the PSA value at the time of the PET
[59]. The high efﬁcacy of blind salvage radiotherapy on the
prostatic fossa at PSA values < 0.5 ng/mL demonstrates that
most patients with BCR after RP at this PSA level actually
experience a local recurrence [60]. In the present review, local
recurrence was detected only in 22.1% (49/222) of all men at a
PSA < 0.5 ng/mL, suggesting that 68Ga-PSMA PET misses
local recurrences (Table 4). This is conﬁrmed by the high
efﬁcacy of salvage radiotherapy (SRT) to the prostatic fossa in
patients with a negative 68Ga-PSMA PET result [36]. Failure
to detect local recurrence is probably attributable to the
inability to distinguish tumour activity from intense activity in
the nearby bladder owing to urinary radiotracer excretion and
to the fact that less aggressive PCa more often returns locally
and less aggressive disease expresses less PSMA [46–49].
In patients with BCR after RP 68Ga-PSMA PET has been
found to have a high management impact and detection rate
[61]; however, the recommendation to perform 68Ga-PSMA
PET after RP to guide salvage treatment is only weak [3].
Although all patients in the different studies included in the
present review underwent RP as primary therapy, not all
treatments between RP and 68Ga-PSMA PET were similar.
Additional treatments after RP inﬂuence the outcome and
detection rate of the 68Ga-PSMA PET. First, ADT at the time
of the PET inﬂuences the chance of having a positive 68Ga-
PSMA PET. In the nomogram presented by Rauscher et al.
[44] for patients with BCR after RP, all patients with a PSA
value >0.2 ng/mL and on ADT at time of the PET have a
~90% chance of having a positive PET. The study by Emmett
et al. [62] showed that the effect of androgen blockade
depends on the patient’s hormonal sensitivity, and impacts
the scan results within 9 days of commencing treatment. In
patients with hormone-sensitive metastatic PCa, androgen
blockage reduces the PSMA intensity. In contrast, androgen
blockage in patients with castrate-resistant PCa signiﬁcantly
increases PSMA intensity and the number of lesions detected
[62]. There is a clear effect, therefore, of ADT on the
performance of 68Ga-PMSA PET, which needs further
evaluation. Second, patients who underwent SRT after RP,
but before 68Ga-PSMA PET, have a decreased risk of having
local recurrence detected on 68Ga-PSMA PET. In most papers
reporting the detection rate of 68Ga-PSMA PET that are
included in this review, both patients with or without ADT at
time of or prior to the PSMA PET were included. Moreover,
a selection of patients underwent radiotherapy to the prostatic
fossa between RP and 68Ga-PSMA PET. This should be
considered when interpreting the results.
Salvage radiotherapy is the last curative treatment possibility
for patients with BCR after RP, and is most effective at low
PSA values [60]; however, SRT is unsuccessful if PCa has
recurred outside the prostatic fossa. Only three studies
describe a patient cohort without additional treatment
between RP and 68Ga-PSMA PET to determine the effect of
68Ga-PSMA PET outcome on SRT planning [30,34,36]. By
detecting PCa recurrence outside the prostatic fossa, the
outcome of 68Ga-PSMA PET changed SRT planning in 34.7%
(42/121) and 39.1% (43/110) patients at PSA values <0.2 and
0.2–0.49 ng/mL, respectively. In the study by Boreta et al.
[34] 68Ga-PSMA PET changed SRT planning in 41.3% (33/
80) of all patients with a PSA value of 0.2–0.59 ng/mL.
Therefore, the use of 68Ga-PSMA PET to prevent
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unsuccessful SRT seems indicated in patients considered for
SRT, even at PSA values < 0.2 ng/mL.
The optimal time to perform 68Ga-PSMA PET is unclear, but
one conclusion can be drawn from the included studies,
namely, 68Ga-PSMA PET has poor sensitivity for local
recurrences, especially at low PSA values. 68Ga-PSMA PET
should therefore be used to exclude metastases rather than to
detect a local recurrence. In patients considered for SRT, the
68Ga PSMA PET should be obtained at a PSA value where
the detection rate is considered high enough to exclude
metastases and a negative 68Ga PSMA PET/CT triggers SRT.
The present review has some limitations. The ﬁrst is inherent
in its design. We did not perform a systematic review and
meta-analysis as not all data were available; therefore, we
were only able to show the reported results of the different
studies. The second limitation is the lack of prospective and
randomized controlled trials included. Most studies included
were retrospective in design and therefore have a possible
selection bias.
A strength of this review is the strict inclusion criteria of
articles included. This enabled adequate assessment of the
speciﬁcity and sensitivity of 68Ga-PSMA PET in detecting
lymph node metastases. Moreover, by excluding papers
describing the location of PCa recurrence after RP and
additional treatments, we presented a well-deﬁned selected
group of patients considered for SRT.
Future studies should focus on strategies to improve the
sensitivity of 68Ga-PSMA PET. To do so, different strategies
could be considered. First, the stimulation of upregulation of
PSMA in PCa cells might improve the sensitivity. In vitro
models showed an upregulation of the PSMA surface levels in
PCa cells by enzalutamide and dutasteride, although the effect
of androgen blockage on the sensitivity of 68Ga-PSMA PET
seems to depend on the phenotype of the PCa [62,63]. More
research is needed to evaluate the exact effect of androgen
blockade on the 68Ga-PSMA PET imaging. Second, next to
the expression of the PSMA receptor, the detection of small
lesions by PET scanners depends both on technical and tracer
characteristics. Improvement of spatial resolution of PET
systems and usage of tracers with higher positron yield and
shorter positron range, such as 18F, might improve the
detection of small lesions [64,65]. In eight patients who
underwent 18F-PSMA-1007 PET/CT and subsequent RP with
extended PLND, the sensitivity and speciﬁcity were 94.7%
and 100%, respectively [66]. Moreover, decreased urinary
clearance of 18F-PSMA-1007 might reduce activity of
radiotracer in the bladder and hence improve detection of
local recurrence [66]. In patients with BCR after RP, the
detection rate of 18F-PSMA-1007 PET/CT was 61.5% (40/65)
and 74.5% (35/47) for patients with PSA values of 0.2–0.49
ng/mL and 0.5–0.99 ng/mL, respectively [67]. The reported
detection rates of 18F-DCFPyL PET/CT in the PSA range of
0.2–0.49 ng/mL and 0.5–0.99 are 59% (17/29) and 69% (20/
29), respectively [68]. In a recent matched-pair comparison,
the accuracy of 68Ga-PSMA PET and 18F-PSMA-1007 PET
was determined in patients with BCR after RP. Diagnostic
performance was similar, however, 18F-PSMA-1007 PET
showed positive lesions that were benign in origin (e.g.
ganglia) ﬁve times more often. Readers of 18F-PSMA PET
should be aware of these potential pitfalls. In addition, future
studies should focus on determining the optimal time to
perform PSMA PET and the effectiveness of SRT after
negative PSMA PET at different PSA values. Lastly, studies
with long-term follow-up are needed to determine the role of
PSMA-guided salvage therapies in clinical practice.
In conclusion, 68Ga-PSMA PET has a very high speciﬁcity
and positive predictive value in detecting pelvic lymph node
metastases, therefore, histological conﬁrmation is not always
necessary if 68Ga-PSMA PET detects pelvic lymph node
metastasis. In contrast, the sensitivity of the 68Ga-PSMA PET
in detecting pelvic lymph node metastases is only moderate
and small lymph node metastases can be missed. 68Ga-PSMA
PET, therefore, cannot yet replace extended PLND to exclude
pelvic lymph node metastases. Based on the available data,
68Ga-PSMA PET seems to have a high management impact
in patients considered for SRT at (early) BCR after RP.
Future studies should focus on improving the sensitivity of
68Ga-PSMA PET, and prospective studies focusing on long-
term outcomes of PSMA-guided therapies are required.
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